Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 8


Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review.

Desouza CV, Shivaswamy V.

Clin Med Insights Endocrinol Diabetes. 2010;3:43-51. Epub 2010 Aug 3.


Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.

Poolsup N, Suksomboon N, Setwiwattanakul W.

ISRN Endocrinol. 2012;2012:798146. doi: 10.5402/2012/798146. Epub 2012 Mar 27.


Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.

Vinaixa M, Rodriguez MA, Samino S, Díaz M, Beltran A, Mallol R, Bladé C, Ibañez L, Correig X, Yanes O.

PLoS One. 2011;6(12):e29052. doi: 10.1371/journal.pone.0029052. Epub 2011 Dec 16.


Risk management in the treatment of type 2 diabetes with pioglitazone.

Derosa G, Salvadeo SA.

Diabetes Metab Syndr Obes. 2009 Jul 1;2:51-60.


Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

Aljada A, Shah KA, Mousa SA.

PPAR Res. 2009;2009:460764. doi: 10.1155/2009/460764. Epub 2009 Aug 19.


Redefining the role of thiazolidinediones in the management of type 2 diabetes.

Barnett AH.

Vasc Health Risk Manag. 2009;5(1):141-51. Epub 2009 Apr 8. Review.


Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetes.

Lee MY, Koh JH, Nam SM, Jung PM, Sung JK, Kim SY, Shin JY, Shin YG, Chung CH.

Yonsei Med J. 2008 Dec 31;49(6):901-8. doi: 10.3349/ymj.2008.49.6.901.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk